

May 6, 2010

To Whom It May Concern

Company: Taisho Pharmaceutical Co., Ltd.  
Representative: Akira Uehara, CEO  
(First Section of TSE: Code 4535)  
Contact: Masaki Tsuboi, General Manager  
Public Relations Section  
(Tel: +81-3-3985-1115)

**Taisho to Repurchase Treasury Stock on the Open Market  
(Treasury stock repurchase based on the Articles of Incorporation  
as stipulated by Article 165, Paragraph 2 of the Japanese Corporation Act)**

Taisho Pharmaceutical Co., Ltd. has announced that it has repurchased treasury stock on the open market, as detailed below. This repurchase was based on the provisions of Article 156 of the Japanese Corporation Act, which has been reinterpreted and applied in accordance with Article 165, Paragraph 3 of the same Act.

1. Type of stock: Taisho Pharmaceutical common stock
2. Period of repurchase: From April 1, 2010 to April 30, 2010  
(execution basis)
3. Amount of stock: 3,366,000 shares
4. Total value of stock: ¥5,782,653,115
5. Method of repurchase: On the open market through the Tokyo Stock Exchange

Notes:

1. Details of Board of Directors resolution about repurchase on March 1, 2010
  - Type of stock: Taisho Pharmaceutical common stock
  - Amount of stock: 6,500,000 shares (upper limit)  
(percentage of total number shares issued: 2.26%)
  - Total value of stock: ¥10,000 million (upper limit)
  - Period of repurchase: From March 8, 2010 to June 30, 2010
2. Cumulative common stock repurchased to date since above Board of Directors' resolution (as of April 30, 2010)
  - Amount of stock: 5,243,000 shares
  - Total value of stock: ¥8,896,539,115